KOD — Kodiak Sciences Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1468748 ·
Last close
$96.80
Market Cap
$6.33B
52W High
$112.79
52W Low
$18.15
ADV30
1,042,205
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -67,098,000 | -66,223,000 | 209,413,000 | 88,678,000 | 196,841,000 |
| Jun 2026 | 0 | — | -66,838,000 | -65,643,000 | 256,811,000 | 125,903,000 | 195,715,000 |
| Mar 2026 | 0 | — | -59,777,000 | -58,158,000 | 306,006,000 | 169,530,000 | 193,905,000 |
| Dec 2025 | 0 | — | -57,453,000 | -56,736,000 | 351,533,000 | 209,862,000 | 194,150,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-158,505,000
Investing CF
$-1,397,000
Financing CF
$181,640,000
CapEx
$-1,397,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.19
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,682,506,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-241,999,000
Pretax Income TTM
$-241,994,000
Interest Exp TTM
—
Analysts
6
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -234,388,000 | -229,967,000 | 351,533,000 | 194,150,000 | 157,383,000 | -136,008,000 |
| Dec 2024 | 0 | -186,849,000 | -176,207,000 | 335,578,000 | 185,290,000 | 150,288,000 | -117,319,000 |
| Dec 2023 | 0 | -277,321,000 | -260,491,000 | 479,372,000 | 213,591,000 | 265,781,000 | -154,183,000 |
| Dec 2022 | 0 | -341,379,000 | -333,823,000 | 666,628,000 | 230,461,000 | 436,167,000 | -206,459,000 |
TTM Snapshot
Revenues TTM
$4,570,000
NetIncome TTM
$-241,994,000
OpCashFlow TTM
—
Assets (Latest)
$256,811,000
Forward EPS
$-3.44
Max Pain — expiry 2026-12-18
max pain strike: $90.00 · spot: $97.81 · call oi: 5,051 · put oi: 2,622
Expected Move to 2026-12-18:
±$20.50
(20.96%) —
implied range
$77.31 –
$118.31
· ATM straddle on $100.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IBRX | ImmunityBio, Inc. | $6.66B | $6.26 | — |
| IMVT | Immunovant, Inc. | $6.87B | $33.21 | — |
| CGON | CG Oncology, Inc. | $7.00B | $78.94 | — |
| SRRK | Scholar Rock Holding Corp | $5.50B | $45.08 | — |
| TWST | Twist Bioscience Corp | $7.43B | $112.00 | — |
News headlines (Yahoo Finance, 1h cache)
Kodiak Sciences Announces Recent Business Highlights and Third Quarter 2026 Financial Results
2026-11-12 21:00 · Yahoo
Kodiak Sciences to Present at Three Upcoming Investor Conferences
2026-11-11 23:43 · Yahoo
Kodiak Sciences (KOD) Stock Looks At A Premium On Its Huge 3 Year Run
2026-11-10 02:10 · Yahoo
Kodiak Sciences (KOD) Could Be 7% Overvalued Following Late Stage Data Update
2026-10-08 19:12 · Yahoo
Kodiak Sciences (KOD) Stock Trades At A Premium On DAYBREAK Trial News
2026-10-08 15:13 · Yahoo
Kodiak Sciences to Present Clinical Data Across All Three Late-Stage Programs at AAO 2026
2026-10-07 11:00 · Yahoo
Kodiak Sciences’ Two Wet AMD Treatments Match Aflibercept in Phase III Study
2026-10-02 18:02 · Yahoo
This week in charts: Kodiak’s big comeback and Hengrui’s dealmaking
2026-10-02 15:00 · Yahoo
Kodiak Sciences More Than Doubles on Eye Disease Trial Results
2026-10-01 14:57 · Yahoo
A $32 Biotech Became a $90 Biotech Overnight. Is It Too Late to Buy Kodiak?
2026-09-30 12:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.